Total Revenue
Vertex Pharmaceuticals Total Revenue decreased by 6.4% to $2.99B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.8%, from $2.77B to $2.99B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows an upward trend with a 12.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
Detailed definition
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer comparison
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.79B | $1.98B | $2.07B | $2.10B | $2.20B | $2.33B | $2.30B | $2.37B | $2.49B | $2.48B | $2.52B | $2.69B | $2.65B | $2.77B | $2.91B | $2.77B | $2.96B | $3.08B | $3.19B | $2.99B |
| QoQ Change | — | +10.6% | +4.5% | +1.2% | +4.7% | +6.3% | -1.4% | +3.1% | +5.0% | -0.4% | +1.4% | +6.9% | -1.7% | +4.8% | +5.1% | -4.9% | +7.0% | +3.8% | +3.7% | -6.4% |
| YoY Change | — | — | — | — | +22.5% | +17.6% | +11.1% | +13.2% | +13.5% | +6.4% | +9.3% | +13.3% | +6.1% | +11.6% | +15.7% | +3.0% | +12.1% | +11.0% | +9.5% | +7.8% |
Product Breakdown
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| TRIKAFTA/KAFTRIO | $2.48B | $2.45B | $2.59B | $2.54B | $2.55B | $2.65B | $2.57B | $2.35B |
| ALYFTREK | — | — | — | $53.90M | $156.80M | $247.00M | $380.10M | $424.40M |
| Other CF product revenues | — | — | $186.90M | $170.80M | $236.10M | $175.80M | $237.40M | $135.90M |
| CASGEVY | — | — | — | — | — | — | — | $42.90M |
| JOURNAVX | — | — | — | — | — | — | — | $29.00M |
| Other CF products | $207.00M | $196.40M | — | — | — | — | — | — |
| Total | $2.69B | $2.65B | $2.77B | $2.77B | $2.96B | $3.08B | $3.19B | $2.99B |
Kalydeco, ORKAMBI, Other CF products, SYMDEKOSYMKEVI were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Pharmaceuticals | $2.77B | $2.96B | $3.08B | $3.19B | $2.99B |
| Total | $2.77B | $2.96B | $3.08B | $3.19B | $2.99B |
Geographic Breakdown
| Segment | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Europe | $735.30M | $967.40M | $806.80M | $847.70M | $832.00M | $826.60M | — | $950.00M |
| Other | $179.95M | — | — | — | $220.33M | $280.10M | — | $261.00M |
| Outsidethe United States | $957.20M | — | — | — | $1.08B | — | $1.11B | — |
| Total | $2.52B | $2.69B | $2.65B | $2.77B | $2.91B | $2.77B | $3.19B | $2.99B |
Outsidethe United States is derived from annual filings.
Total Revenue at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's total revenue?
- Vertex Pharmaceuticals (VRTX) reported total revenue of $2.99B in Q1 2026.
- How has Vertex Pharmaceuticals's total revenue changed year-over-year?
- Vertex Pharmaceuticals's total revenue increased by 7.8% year-over-year, from $2.77B to $2.99B.
- What is the long-term trend for Vertex Pharmaceuticals's total revenue?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's total revenue has grown at a 12.2% compound annual growth rate (CAGR), from $7.57B to $12.00B.
- What does total revenue mean?
- The total amount of money a company brings in from selling its products and services.